Quidel Corporation (QDEL)

Currency in USD
14.66
-0.19(-1.28%)
Real-time Data·
QDEL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.1115.50
52 wk Range
9.9235.58
Key Statistics
Prev. Close
14.85
Open
14.96
Day's Range
14.11-15.5
52 wk Range
9.92-35.58
Volume
1.41M
Average Vol. (3m)
1.61M
1-Year Change
-42.8683%
Book Value / Share
26.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QDEL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.67
Upside
+0.05%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Quidel Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Analyst Ratings

1 Buy
1 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 14.67
(+0.05% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Hold18.00+22.78%13.00MaintainJul 08, 2026
JPMorgan
Sell12.00-18.14%11.00MaintainJul 01, 2026
Jefferies
Hold12.50-14.73%-MaintainJun 29, 2026
UBS
Hold12.00-18.14%17.00MaintainMay 07, 2026
Jefferies
Hold12.50-14.73%35.00DowngradeMay 07, 2026

Quidel Corporation SWOT Analysis


Analyst Perspectives
Learn about analyst price targets ranging from $50 to $61, reflecting varied views on QuidelOrtho's growth potential and market opportunities
Product Launch Hurdles
Delve into the challenges faced by QuidelOrtho in launching new products, particularly the delayed Savanna launch, and its impact on market position
Margin Expansion Drive
Explore QuidelOrtho's strategic focus on cost structure realignment and margin expansion, potentially leading to long-term earnings growth
Financial Resilience
QuidelOrtho's strong Q4 results and reaffirmed FY'25 guidance showcase the company's potential for growth and ability to meet future targets
Read full SWOT analysis

Quidel Corporation Earnings Call Summary for Q2/2026

  • QuidelOrtho posted Q2 adjusted EPS of $0.13, beating estimates of a $0.04 loss, with revenue of $630.9M slightly above forecasts.
  • Company slashed full-year revenue guidance to $2.52B-$2.60B and withdrew free cash flow guidance amid China headwinds and weaker respiratory outlook.
  • China revenue plunged 23% YoY due to policy changes; core businesses outside China grew 6%, with adjusted EBITDA margin expanding 310bps to 20%.
  • Net debt leverage stands at 4.3x EBITDA with $2.87B total debt; stock plummeted 21% in after-hours trading despite initial gains.
  • Management projects Q3 EPS of $0.85 and Q4 EPS of $1.08, citing conservative respiratory season assumptions and ongoing operational improvements.
Last Updated: 08/06/2026, 05:55 PM
Read Full Transcript

Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
0.13 / -0.04
Revenue / Forecast
630.9M / 619.53M
EPS Revisions
Last 90 days

QDEL Income Statement

Compare QDEL to Peers and Sector

Metrics to compare
QDEL
Peers
Sector
Relationship
P/E Ratio
−1.0x−2.8x−0.3x
PEG Ratio
0.01−0.100.00
Price / Book
0.6x1.9x2.6x
Price / LTM Sales
0.4x2.0x3.1x
Upside (Analyst Target)
−15.1%13.1%47.6%
Fair Value Upside
Unlock20.3%5.6%Unlock

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
45.62M66.52%629.49M
Other Institutional Investors
52.66M33.48%726.71M
Public Companies & Retail Investors
0.000.00%0.00
Total
98.28M100.00%1.36B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.16.34%11,202,523154,595
FMR LLC11.45%7,850,759108,340

People Also Watch

38.82
VIAV
+0.66%
868.47
LITE
-1.23%
124.280
AAOI
-3.73%
288.99
COHR
-0.36%
1,601.07
SNDK
+0.03%

FAQ

What Is the Quidel (QDEL) Stock Price Today?

The Quidel stock price today is 14.66 USD.

What Stock Exchange Does Quidel Trade On?

Quidel is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Quidel?

The stock symbol for Quidel is "QDEL."

What Is the Quidel Market Cap?

As of today, Quidel market cap is 1.01B USD.

What Is Quidel's Earnings Per Share (TTM)?

The Quidel EPS (TTM) is -15.40.

When Is the Next Quidel Earnings Date?

Quidel will release its next earnings report on Nov 04, 2026.

From a Technical Analysis Perspective, Is QDEL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Quidel Stock Split?

Quidel has split 0 times.

How Many Employees Does Quidel Have?

Quidel has 6500 employees.

What is the current trading status of Quidel (QDEL)?

As of Aug 21, 2026, Quidel (QDEL) is trading at a price of 14.66 USD, with a previous close of 14.85 USD. The stock has fluctuated within a day range of 14.11 USD to 15.50 USD, while its 52-week range spans from 9.92 USD to 35.58 USD.

What Is Quidel (QDEL) Price Target According to Analysts?

The average 12-month price target for Quidel is 14.67 USD, with a high estimate of 20 USD and a low estimate of 12 USD. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +0.05% Upside potential.

What Is the QDEL Premarket Price?

QDEL's last pre-market stock price is 14.99 USD. The pre-market share volume is 4,620.00, and the stock has decreased by 0.14, or 0.94%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.